Worth stating the null on SURMOUNT-OSA before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
Journal club: SURMOUNT-OSA and a hard endpoint in a soft field posts 31–52
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
This follows post #31 rather than contradicting it.
A note on how SURMOUNT-OSA gets discussed rather than on SURMOUNT-OSA itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.
Coming back to post #31, because the follow-up matters more than the original answer.
The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.
That is all I can say without guessing.
Post #31 and I disagree about the size of the effect, not about the direction.
If you are new and reading this thread for the answer to SURMOUNT-OSA: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.
Taking post #35 at face value and following it one step further.
Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later.
Nothing above should be read as advice about what anyone else should do.
Collapsed as off-topic by two members at trust level 3 or above
My position on SURMOUNT-OSA is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
I am confident about the direction and much less about the magnitude.
The failure mode on SURMOUNT-OSA is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
Taking post #40 at face value and following it one step further.
Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything that follows.
If anyone has run this properly I would rather read that than my own guess.
This settles it for me, at least until somebody posts a reason it should not.
Answering the question post #42 raises rather than the one it answers.
The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.
The general case is well covered; this is the awkward specific one.
SURMOUNT-OSA is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two parallel trials addressed the confounder directly.
Post #48 is right about the mechanism and I think understates the practical bit.
The figures usually contain the finding and the text usually contains the interpretation. Separating them for the first twenty minutes is a discipline worth keeping.
Filing this under things that are true until someone shows me otherwise.
Answering the question post #49 raises rather than the one it answers.
Speaking only to SURMOUNT-OSA as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.
The arithmetic in post #49 is right; the assumption feeding it is the part to check.
Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
The short answer was in the first line; everything after is the working.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold?
The question in the title: Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? I will give what I have already checked below so nobody repeats it. Reading SUSTAIN 6 ( N Engl J Med ,…
|
+60 | 66 | 12k | 16mo |
|
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. The question about STEP 4 that I actually want…
|
+81 | 90 | 54k | 9mo |
|
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
|
2 | 52k | 1mo | |
|
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Posting a small dataset on SELECT. It is mine, it is…
|
4 | 1.3k | 1mo | |
|
Journal club: how we handle discontinuation in obesity trials
On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
|
2 | 1.9k | 12mo |
Related topics — sharing the tags randomised trial, effect size, journal club
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Retatrutide mass and identity: what a report should show
Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
|
+65 | 71 | 4.6k | 13mo |
|
Journal club: STEP 4 and what a withdrawal design can prove
On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
|
+61 | 65 | 2k | 13mo |
|
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…
|
+2 | 6 | 18k | 17mo |
|
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like
On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion. Two things I would like separated before anyone answers on…
|
+41 | 46 | 1.2k | 4mo |
|
Journal club: STEP-HFpEF and symptom endpoints — a second dataset
On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Posting a small dataset on step-hfpef and symptom endpoints. It is mine,…
|
+11 | 15 | 4k | 10mo |